DATA GRAPHICS | Data Byte
Yescarta crosses the blockbuster line; momentum remains strong
Gilead leads the CAR T pack, with multiple growth drivers in the near future
February 11, 2023 12:39 AM UTC
Five years after the world’s first CAR T therapy was approved, 2022 saw the first recorded blockbuster sales from the therapeutic modality, with Gilead’s Yescarta reaching $1.16 billion.
The commercial growth of Yescarta axicabtagene ciloleucel was partly propelled by expansion of its FDA label in April 2022 to include second-line treatment of large B cell lymphoma (LBCL)...